Medicine
QuilliChew ER 20 mg extended-release chewable tablet
QuilliChew ER 20 mg extended-release chewable tablet is a prescription medicine containing Methylphenidate for oral use, marketed by NextWave Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted from 15ºC to 30ºC…
Key facts
- Active ingredient (INN)
- Methylphenidate
- Brand
- QuilliChew ER
- Strength
- 20 mg
- Dosage form
- Extended-release chewable tablet
- Route
- Oral
- Packs
- 100 tablets, 30 tablets
- Marketing authorisation holder
- NextWave Pharmaceuticals
- Manufacturer
- NextWave Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted from 15ºC to 30ºC (59ºF to 86ºF).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CII
- ATC code
- N06BA04 Methylphenidate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 April 2016
- Identifiers
- RxCUI 1727443, 1727450, 1734928 +3DailyMed set ID defc1205-8e90-4b1e-b862-05e4c35c7364NDC 24478-074Application NDA207960
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, chewable, extended release in 1 bottle | 24478-074-01 | NextWave Pharmaceuticals | 18 April 2016 |
| 30 tablet, chewable, extended release in 1 bottle | 24478-074-02 | NextWave Pharmaceuticals | 14 September 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Methylphenidate
Clinical summary
Methylphenidate is a central nervous system stimulant indicated for the treatment of attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults, among other approved uses. MedsAcross supplies Methylphenidate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MethylphenidateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ritalin prescribing information (Sandoz) · U.S. National Library of Medicine, DailyMed
- Tuzulby: European public assessment report (EPAR) · European Medicines Agency
Need QuilliChew ER 20 mg extended-release chewable tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.